Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium breve ccfm1025
- Development stage
- Unknown
- Lead developer
- Jiangnan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium breve CCFM1025 is a live probiotic (psychobiotic) bacterial strain developed by researchers at Jiangnan University in China. As a live biotherapeutic product, it targets the gut-brain axis to modulate neurobiological pathways associated with mood and stress. The strain influences the serotonergic system by regulating tryptophan and serotonin metabolism, and it modulates the hypothalamic-pituitary-adrenal (HPA) axis and glucocorticoid receptor (Nr3c1) expression. Clinical studies have investigated its efficacy in treating major depressive disorder (MDD) and stress-induced insomnia, showing potential to increase brain-derived neurotrophic factor (BDNF) levels and activate the pCREB-c-Fos pathway. Additionally, patent filings suggest applications in inflammatory bowel disease and obesity management.
- Other names
- B. breve CCFM1025
02
Targets
GR (Glucocorticoid receptor)BDNF (Brain-derived neurotrophic factor)
Beyond the preview
Go deeper on bifidobacterium breve ccfm1025.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium breve ccfm1025.